[Form 4] Crinetics Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Crinetics Pharmaceuticals (CRNX) reporting insider transactions by Dana Pizzuti. The filing shows on 09/02/2025 the reporting person acquired 5,000 shares of common stock by exercising options at an exercise price of $16.89 and simultaneously sold 5,000 shares in open-market transactions under a Rule 10b5-1 plan at a volume-weighted average price of $32.10 per share (range $32.00–$32.24). Following these transactions the reporting person beneficially owned 96,270 shares of common stock and directly held 84,042 shares underlying vested and unvested stock options that remain outstanding. The sale was effected automatically pursuant to a 10b5-1 trading plan adopted May 21, 2025.

Insights

Securities Analyst

TL;DR: Officer exercised options and sold equal shares under a pre-established 10b5-1 plan; transaction appears procedural, not a sudden disposition.

The report documents a contemporaneous option exercise at $16.89 per share and an open-market sale of the same number of shares at a VWAP of $32.10 on 09/02/2025. The sale was executed under a Rule 10b5-1 plan adopted 05/21/2025, indicating the transactions followed a pre-set trading arrangement. Post-transaction beneficial ownership is disclosed as 96,270 shares, and 84,042 option-derived shares remain outstanding. For investors, this clarifies the officer converted equity and recycled a portion into cash through an automated plan rather than an ad hoc sale.

Corporate Governance Expert

TL;DR: Use of a documented 10b5-1 plan and attorney-in-fact signature show adherence to insider-trading controls and disclosure rules.

The Form 4 shows the reporting person is an officer (Chief Medical and Development Officer) and that the sale was made pursuant to a Rule 10b5-1 trading plan adopted May 21, 2025. The form is signed by an attorney-in-fact, consistent with delegated execution practices. These elements reflect compliance with Section 16 reporting and insider-trading safe-harbor procedures. The filing does not disclose any accelerated vesting, unusual compensation changes, or other governance issues.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pizzuti Dana

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Med and Dev Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		M		5,000	A	$16.89	101,270	D
Common Stock	09/02/2025		S(1)		5,000	D	$32.1(2)	96,270	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.89	09/02/2025		M			5,000	(3)	10/10/2032	Common Stock	5,000	$0	84,042	D

Explanation of Responses:

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.

2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $32.10 per share. The range of sales prices on the transaction date was $32.00 to $32.24 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

3. The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

	/s/ Tobin Schilke, as attorney-in-fact	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dana Pizzuti (CRNX) do on 09/02/2025?

The reporting person exercised options for 5,000 shares at $16.89 per share and sold 5,000 shares in open-market transactions at a VWAP of $32.10 per share on 09/02/2025.

Was the sale by the CRNX officer part of a 10b5-1 plan?

Yes. The sale was effected automatically pursuant to a Rule 10b5-1 trading plan adopted May 21, 2025.

How many shares does the reporting person own after these transactions?

Following the reported transactions the reporting person beneficially owned 96,270 shares of common stock.

What was the sale price range and VWAP for the shares sold?

The filing reports a volume-weighted average price of $32.10 per share and a sale price range of $32.00 to $32.24 on the transaction date.

What option holdings remain after the transactions?

The report shows 84,042 shares underlying stock options remain beneficially owned by the reporting person following the transactions.